NCT06702605View on ClinicalTrials.gov

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Relapsed/Refractory Peripheral T Cell Lymphoma
Interventions
DRUG

XNW5004 tablets

XNW5004 will be administered orally as tablets.

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY